NASDAQ:MGTXMeiraGTx Stock Price, Forecast & News

MeiraGTx's stock was trading at $14.10 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, MGTX shares have increased by 5.2% and is now trading at $14.84. View which stocks have been most impacted by Coronavirus.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MeiraGTx in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for MeiraGTx.

MeiraGTx is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for MeiraGTx.

MeiraGTx Holdings PLC (NASDAQ:MGTX) posted its earnings results on Thursday, May, 7th. The company reported ($0.43) EPS for the quarter, beating the consensus estimate of ($0.48) by $0.05. The business earned $4.21 million during the quarter. MeiraGTx had a negative net margin of 313.70% and a negative return on equity of 29.96%. View MeiraGTx's earnings history.

2 brokers have issued 12-month price objectives for MeiraGTx's shares. Their forecasts range from $40.00 to $45.00. On average, they anticipate MeiraGTx's share price to reach $42.50 in the next year. This suggests a possible upside of 186.4% from the stock's current price. View analysts' price targets for MeiraGTx.

Headlines about MGTX stock have trended somewhat positive this week, InfoTrie Sentiment reports. InfoTrie identifies negative and positive news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. MeiraGTx earned a media sentiment score of 2.0 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View the latest news aboutMeiraGTx.

MeiraGTx saw a decline in short interest in May. As of May 15th, there was short interest totaling 579,000 shares, a decline of 7.5% from the April 30th total of 626,000 shares. Based on an average trading volume of 114,000 shares, the short-interest ratio is currently 5.1 days. Currently, 2.0% of the company's shares are short sold. View MeiraGTx's Current Options Chain.

Some companies that are related to MeiraGTx include Bill.com (RVMD), Adverum Biotechnologies (ADVM), SpringWorks Therapeutics (SWTX), Sangamo Therapeutics (SGMO), Twist Bioscience (TWST), Mesoblast (MESO), Editas Medicine (EDIT), Adaptimmune Therapeutics (ADAP), Regenxbio (RGNX), I-Mab (BDTX), Cortexyme (CRTX), Coherus Biosciences (CHRS), Beam Therapeutics (BEAM), Translate Bio (TBIO) and NanoString Technologies (NSTG). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other MeiraGTx investors own include AbbVie (ABBV), Crispr Therapeutics (CRSP), Inovio Pharmaceuticals (INO), Kadmon (KDMN), Viking Therapeutics (VKTX), Advanced Micro Devices (AMD), Corbus Pharmaceuticals (CRBP), InVitae (NVTA), Sorrento Therapeutics (SRNE) and Canopy Growth (CGC).

(MGTX) raised $75 million in an initial public offering on Friday, June 8th 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Barclays and Evercore ISI acted as the underwriters for the IPO and Chardan was co-manager.

MeiraGTx trades on the NASDAQ under the ticker symbol "MGTX."

MeiraGTx's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Orbimed Advisors LLC (9.59%), Johnson & Johnson Innovation JJDC Inc. (7.76%), BlackRock Inc. (3.29%), Prosight Management LP (1.52%), State Street Corp (0.96%) and Alyeska Investment Group L.P. (0.93%). Company insiders that own MeiraGTx stock include Alexandria Forbes, Joel S Marcus, Life Sciences Maste Perceptive, Nicole Seligman, Richard Giroux, Stuart Naylor and Thomas E Shenk. View institutional ownership trends for MeiraGTx.

MGTX stock was sold by a variety of institutional investors in the last quarter, including Squarepoint Ops LLC, BlackRock Inc., Morgan Stanley, UBS Group AG, Ensign Peak Advisors Inc, Victory Capital Management Inc., Victory Capital Management Inc., and SG Americas Securities LLC. Company insiders that have sold MeiraGTx company stock in the last year include Alexandria Forbes, Joel S Marcus, Richard Giroux, Stuart Naylor, and Thomas E Shenk. View insider buying and selling activity for MeiraGTx.

MGTX stock was bought by a variety of institutional investors in the last quarter, including Johnson & Johnson Innovation JJDC Inc., Orbimed Advisors LLC, Alps Advisors Inc., Rhenman & Partners Asset Management AB, Prosight Management LP, JPMorgan Chase & Co., Fort Sheridan Advisors LLC, and AQR Capital Management LLC. Company insiders that have bought MeiraGTx stock in the last two years include Life Sciences Maste Perceptive, and Nicole Seligman. View insider buying and selling activity for MeiraGTx.

Shares of MGTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of MGTX stock can currently be purchased for approximately $14.84.

MeiraGTx has a market capitalization of $554.42 million and generates $13.29 million in revenue each year. The company earns $-54,750,000.00 in net income (profit) each year or ($1.65) on an earnings per share basis. MeiraGTx employs 68 workers across the globe.

The official website for MeiraGTx is www.meiragtx.com.

MeiraGTx's mailing address is 450 East 29thStreet 15thFloor, NEW YORK NY, 10016. The company can be reached via phone at 646-860-7985 or via email at [email protected]